Onyx Biotec Past Earnings Performance

Past criteria checks 3/6

Onyx Biotec has been growing earnings at an average annual rate of 64.4%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 36.1% per year. Onyx Biotec's return on equity is 12.2%, and it has net margins of 5.6%.

Key information

64.4%

Earnings growth rate

62.5%

EPS growth rate

Pharmaceuticals Industry Growth	17.5%
Revenue growth rate	36.1%
Return on equity	12.2%
Net Margin	5.6%
Last Earnings Update	31 Mar 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Onyx Biotec makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:ONYX Revenue, expenses and earnings (INR Millions)
Date	Revenue	Earnings	G+A Expenses
31 Mar 24	537	30	60
31 Mar 23	395	18	105
31 Mar 22	449	34	87

Quality Earnings: ONYX has high quality earnings.

Growing Profit Margin: ONYX's current net profit margins (5.6%) are higher than last year (4.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ONYX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare ONYX's past year earnings growth to its 5-year average.

Earnings vs Industry: ONYX earnings growth over the past year (64.4%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: ONYX's Return on Equity (12.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 13:12
End of Day Share Price	2024/12/26 00:00
Earnings	2024/03/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Onyx Biotec Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution